% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • tredleon tredleon Aug 7, 2012 10:40 AM Flag


    It is hard to imagine who is selling at these levels. As the Wedbush report indicates, OMER has several low-risk milestones coming up in the second half of the year. Solid data from the second OMS302 Phase III trial, which is a practical certainty given the results from the first trial, should be enough to push the valuation on this stock above $400M (versus less than $200M today). I used to think when I saw action like this that the "experts"/insiders knew something that was not known to the retail world, but recently I have seen a number of stocks get dragged down for no reason, only to spike sharply when milestones are achieved, so I will continue to average down at these levels.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
15.76-0.09(-0.57%)Dec 1 4:00 PMEST